A detailed history of Graham Capital Management, L.P. transactions in Mersana Therapeutics, Inc. stock. As of the latest transaction made, Graham Capital Management, L.P. holds 50,970 shares of MRSN stock, worth $129,973. This represents 0.0% of its overall portfolio holdings.

Number of Shares
50,970
Holding current value
$129,973
% of portfolio
0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$2.0 - $4.45 $101,940 - $226,816
50,970 New
50,970 $102,000
Q4 2023

Feb 14, 2024

SELL
$1.11 - $2.34 $38,864 - $81,930
-35,013 Reduced 74.78%
11,811 $27,000
Q3 2023

Nov 22, 2023

SELL
$1.06 - $3.91 $28,535 - $105,257
-26,920 Reduced 36.5%
46,824 $59,000
Q2 2023

Aug 14, 2023

BUY
$3.08 - $9.55 $227,131 - $704,255
73,744 New
73,744 $242,000
Q2 2022

Aug 15, 2022

BUY
$2.84 - $5.0 $576,710 - $1.02 Million
203,067 New
203,067 $938,000

Others Institutions Holding MRSN

About Mersana Therapeutics, Inc.


  • Ticker MRSN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,169,296
  • Market Cap $248M
  • Description
  • Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...
More about MRSN
Track This Portfolio

Track Graham Capital Management, L.P. Portfolio

Follow Graham Capital Management, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Graham Capital Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Graham Capital Management, L.P. with notifications on news.